Loading
Preparing stock search
Loading the search box, recent screening context, and the surrounding editorial guidance.
Help keep us running — this site is free to use and we cover the running costs ourselves. We're open to sponsors and advertising to keep it online. Get in touch.
Heads up — we're updating the site with more recent financial data over the coming days. Thanks for being patient with us.
Loading
Loading the search box, recent screening context, and the surrounding editorial guidance.
Company report
Review the methodology status, formula details, and supporting context for BEAM.
Methodology
AAOIFI
DJIM
S&P Shariah
Company
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Debt ratio
Formula
Total Interest-Bearing Debt / Market Capitalization (or Avg for AAOIFI/DJIM)
Thresholds
Cash ratio
Formula
(Cash + Interest-Bearing Securities) / Market Capitalization
Thresholds
Analysis
Haram revenue
Formula
Impermissible Revenue / Total Revenue
Thresholds
Methodology